Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Cash Flow (2016 - 2025)

KalVista Pharmaceuticals' Net Cash Flow history spans 10 years, with the latest figure at -$39.0 million for Q2 2025.

  • On a quarterly basis, Net Cash Flow fell 543.2% to -$39.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$29.8 million, a 28.1% decrease, with the full-year FY2025 number at $97.8 million, up 521.09% from a year prior.
  • Net Cash Flow hit -$39.0 million in Q2 2025 for KalVista Pharmaceuticals, down from $9.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for KALV hit a ceiling of $9.3 million in Q4 2024 and a floor of -$39.0 million in Q2 2025.
  • Historically, Net Cash Flow has averaged -$7.6 million across 3 years, with a median of -$58000.0 in 2024.
  • Biggest five-year swings in Net Cash Flow: soared 99.16% in 2024 and later plummeted 543.2% in 2025.
  • Tracing KALV's Net Cash Flow over 3 years: stood at $8.9 million in 2023, then rose by 5.27% to $9.3 million in 2024, then plummeted by 518.54% to -$39.0 million in 2025.
  • Business Quant data shows Net Cash Flow for KALV at -$39.0 million in Q2 2025, $9.3 million in Q4 2024, and -$58000.0 in Q3 2024.